Diabetes Drug May Slow Parkinson’s Disease
Exenatide was studied in a randomized, double blind, placebo controlled study. The drug is a glucagon like peptide 1(GLP-1) receptor agonist which improved off time and benefits persisted weeks after the drug was discontinued. This may suggest the drug can slow down progression of Parkinson’s disease.
Exenatide showed in several animal models of Parkinson’s disease. A pilot study of patients with moderately advanced Parkinson’s disease showed motor and cognitive impairment over 12 months. This study entered 62 patients with idiopathic Parkinson’s disease. Patients received 2mg Exenatide subcutaneous injection weekly for 48 weeks followed by a 12 week washout period. The placebo group worsened gradually over the year. While Exenatide group slightly improved, even during the washout period.
Loss of neuronal insulin resistance in Parkinson’s disease and other neurodegenerative diseases such as Alzheimer’s disease, may be playing a role in the cause of the disease. Larger study to investigate if Exenatide is a new symptomatic agent or neuro-protective agent is warranted.
Citation: Diabetes Drug May Slow Parkinson’s Disease – Medscape – Aug 14, 2017